Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Cue Biopharma, Inc. (CUE) reported a Q3 loss of $0.17 per share, which was better than the Zacks Consensus Estimate of a $0.20 loss. This is an improvement from the $0.24 loss per share reported a year ago.
November 14, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cue Biopharma reported a Q3 loss of $0.17 per share, beating the expected loss of $0.20 and showing improvement from last year's $0.24 loss.
Cue Biopharma's reported loss per share was better than expected, which is typically seen as a positive indicator for the stock price. The improvement from the previous year's loss also suggests positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100